MBBS (Hons), FCICM, FRACP, PGDipEcho Claire is a senior intensive care specialist, and became Director of ICU in 2020. Originally from Tasmania, Claire completed her medical degree in Hobart in 1999. After training at both The Alfred and Barwon Health, Claire began work as a Specialist in Barwon Health ICU in 2009. Major clinical projects include developing the Paediatric ICU program in University Hospital Geelong. Her work in this area was a significant factor in UHG being awarded the Victorian Premier’s Health Care Secretary Award for Improving Patient Outcomes and Patient Experience in 2014. Claire has a strong interest in education, having involvement with Deakin University, and ICU Supervisor of Training. Claire is also involved in Quality and Safety activities and is current Chair of the Blood and Blood Products Committee.
Clinical leadership
Claire became Director of Intensive Care at University Hospital Geelong in 2020. She has undertaken the Harvard Emerging Women Executives in Health Care Program, and is Chair of the Barwon Health Blood and Blood Products Committee, and led the development of the Barwon Health Paediatric Critical Care Program from 2011-2018.
Latest news:
-
Thursday, August 26, 2021 - 01:57
JAMA BaSICS rate: Slower vs faster fluid challenge in critically ill patients not significantly reduce 90-day mortality. In addition there was a lower use of vasopressors on day 3 in the slower infusion rate group. Adds to SPLIT and SMART trials.
Monday, August 23, 2021 - 13:54NEJM Convalescent plasma RCT for high-risk patients present to ED within 7 days after the onset of symptoms = no difference disease progression
Monday, August 23, 2021 - 12:27NEJM VITT review 237 suspected from 24 million Oxford-Astra Zeneca doses, incidence at least 1:100,000 >50 years, 1:50,000 <50 years, occurs 5-30 days after first dose. Extensive thrombotic sites, cerebral venous thrombosis dominant. Low platelets, increased D-dimer, reduced fibrinogen associated worse outcomes. Overall case fatality rate 23%, highest in patients with both ICH and platelet count below 30,000. No therapeutic options proven effective, although IVIG, corticosteroids, plasma exchange, and non-heparin anticoagulation are used.
Sunday, August 22, 2021 - 19:03JC DOREMI RCT reports no difference in composite primary outcome with milrinone vs dobutamine for cardiogenic shock (49% M vs 54% D, RR, 0.90; 95% CI, 0.69 to 1.19; P=0.47). No difference in secondary outcomes. It was powered to detect a large effect.
Sunday, August 22, 2021 - 11:21REMAP-CAP, ACTIV-4a, and ATTACC harmonised multiplatform, randomized trial 2244 non-ICU patients with COVID- for every 1000 patients, therapeutic anticoagulation vs thromboprophylaxis expected to result in 40 additional patients surviving to hospital discharge without organ support, and 7 major bleeds.